A novel hypomorphic splice variant in EIF2B5 gene is associated with mild ovarioleukodystrophy

Ann Clin Transl Neurol. 2020 Sep;7(9):1574-1579. doi: 10.1002/acn3.51131. Epub 2020 Aug 15.

Abstract

Objective: To identify the genetic cause in an adult ovarioleukodystrophy patient resistant to diagnosis.

Methods: We applied whole-exome sequencing (WES) to a vanishing white matter disease patient associated with premature ovarian failure at 26 years of age. We functionally tested an intronic variant by RT-PCR on patient's peripheral blood mononuclear cells (PBMC) and by minigene splicing assay.

Results: WES analysis identified two novel variants in the EIF2B5 gene: c.725A > G (p.Tyr242Cys) and an intronic noncanonical mutation (c.1156 + 13G>A). This intronic mutation resulted into generation of various isoforms both in patient's PBMC and in the minigene splicing assay, showing that ~20% residual wild-type isoform is still expressed by the intronic-mutated allele alone, concordant with an hypomorphic effect of this variant.

Conclusion: We report two novel variants in EIF2B5, one of them a noncanonical intronic splice variant, located at a +13 intronic position. This position is mutated only in 0.05% of ClinVar intronic mutations described so far. Furthermore, we illustrate how minigene splicing assay may be advantageous when validating splice-altering variants, in this case highlighting the coexistence of wild-type and mutated forms, probably explaining this patient's milder, late-onset phenotype.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Eukaryotic Initiation Factor-2B / genetics*
  • Exome Sequencing
  • Female
  • Humans
  • Leukoencephalopathies / diagnosis*
  • Leukoencephalopathies / genetics*
  • Magnetic Resonance Imaging
  • Ovarian Diseases / diagnosis*
  • Ovarian Diseases / genetics*

Substances

  • EIF2B5 protein, human
  • Eukaryotic Initiation Factor-2B

Supplementary concepts

  • Vanishing White Matter Leukodystrophy with Ovarian Failure

Grants and funding

This work was funded by Miguel Servet program grant CPII16/00016; Ministerio de Economia, Industria y Competividad grant FJCI‐2016‐28811; ALE‐ELA España grant ; CIBERER grant ACCI14‐759; Autonomous Government of Catalonia grants 2014SGR1430 and 2017SGR1206; Fundació la Marató de TV3 grant 345/C/2014; PERIS grant SLT002/16/00174; CERCA Program / Generalitat de Catalunya grant ; Instituto de Salud Carlos III grants FIS PI14/00581, CPII16/00016, and CD19/00221.